The epidermal growth factor receptor as a target for gastrointestinal cancer therapy

Current Treatment Options in Oncology

Volumn 5, Issue 5, 2004, Pages 393-403

  Tedesco, Karen L ^b   Lockhart, A Craig ^b   Berlin, Jordan D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AMINOTRANSFERASE; CAPECITABINE; CELECOXIB; CELL PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PELITINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ACNE; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESEARCH; CANCER THERAPY; CELL PROLIFERATION; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA FLANKING REGION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG SCREENING; ENZYME DEFECT; ESOPHAGUS CANCER; FATIGUE; FEVER; FOLLICULITIS; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; LABORATORY; LIGAND BINDING; NONHUMAN; PANCREAS CANCER; PROGNOSIS; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PUSTULE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 8344229890     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0029-z     Document Type: Review

References (48)

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
2. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29:3-9.
3. Lichtner RB, Menrad A, Sommer A, et al.: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001, 61:5790-5795.
4. Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics 2004. CA Cancer J Clin 2004, 54:8-29.
5. Gotoh M, Kawabe S, Takiuchi H, et al.: EGFR and cyclin D1 are possible predictors of sensitivity to chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (SCC) [abstract]. Proc Am Soc Clin Oncol 2002, 21:164a.
6. Wilkinson NW, Smiley S, Roukhadze E, et al.: Epidermal growth factor receptor (EGFR) expression correlates with histologic grade in adenocarcinoma of the esophagus. J Gastrointest Surg 2004, 8:448-453.
7. Gibson MK, Abraham S, Wu T-T, et al.: Epidermal growth factor receptor, p53 mutation and pathologic response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy [abstract]. Clin Cancer Res 2003, 9(17):6461-6468.
8. Song HS, Kim IH, Sohn SS, et al.: Prognostic significance of p53, Rb, EGFR, and c-erbB2 genes in curatively resected gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22 263.
9. Kopp R, Ruge M, Rothbauer E, et al.: Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002, 22 1161-1167.
10. Garcia I, Vizoso F, Martin A, et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003, 10 234-241.
11. Malecka-Panas E, Fligiel SE, Relan NK, et al.: Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats. Carcinogenesis 1996, 17 233-237.
12. Roberts RB, Min L, Washington MK, et al.: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis, Proc Natl Acad Sci U SA 2002, 99:1521-1526.
13. Brunton VG, Ozanne BW, Paraskeva C, et al.: A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 1997, 14:283-293.
14. Messa C, Russo F, Caruso, MG, et al.: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998, 37:285-289.
15. Kluftinger AM, Robinson BW, Quenville NF, et al: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992, 1:97-105.
16. Steele RJ, Kelly P, Ellul B, et al.: Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990, 77:1352-1354.
17. Koretz K, Schlag P, Moller P, et al.: Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol 1990, 416:343-349.
18. Mayer A, Takimoto M, Fritz E, et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454-2460.
19. McKay JA, Murray LJ, Curran S, et al.: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002, 38:2258-2264.
20. Chang, SA, Chang, AY, Putti TC, et al.: Clinical and pathological correlations of epidermal growth factor receptor in patients with hepatoma [abstract]. Proc Am Soc Clin Oncol 2002, 21 145a.
21. Amador ML, Oppenheimer D, Maitra A, et al.: Genetic-based rational combination of ZD1839 and CI-1040 in biliary tract carcinoma [abstract]. Proc Am Soc Clin Oncol 2004, 125.
22. Gibbs JF, Sreekumar B, Hylander B, et al.: Low Incidence of EGFR and Her2/neu positivity in pancreatic cancer [abstract] Proc Am Soc Clin Oncol 2004, 134.
23. Abbruzzese, JL, Rosenberg, A, Xiong, Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:130a.
24. Uegaki K, Nio Y, Inoue Y, et al.: Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997, 17 3841-3847.
25. Buchsbaum DJ, Bonner JA, Grizzle WE, et al.: Treatment of pancreatic xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002, 54:1180-1193.
26. Radovich, D, Kelsen, D, Shah M, et al.: OSI-774 in advanced esophageal cancer: a phase II study [abstract]. Proc Am Soc Clin Oncol 2004, 23:4077.
27. Van Groeningen C, Richel D, Giacconi G, et al.: Gefitinib phase-II study in second-line treatment of advanced esophageal cancer [abstract]. Proc Am Soc Clin Oncol 2004, 23:4022.
28. Rojo F, Tabernero J, Van Cutsem E, et al.: Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD 1839) [abstract]. Proc Am Soc Clin Oncol 2003, 22:191.
29. Doi T, Koizumi W, Siena S, et al.: Efficacy, tolerability, and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:258.
30. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6 2053-2063.
31. Braun AH, Dirsch O, Hilger R-A, et al: Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells. Proc Am Soc Clin Oncol 2002, 21:329-335.
32. Hammond LA, Figueroa J, Schwartzberg L, et al.: Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI , in combination with 5-fluorouracil (5FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001, 20:544.
33. Cho CD, Fisher GA, Halsey JZ, et al.: A phase I study of ZD1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5FU), and leucovorin (LV) in advanced solid malignancies. Proc Am Soc Clin Oncol 2002, 21:38.
34. Basche ML, Pierson AS, Holden SN, et al.: A phase I trial of ZD1839 (Z) with capecitabine (Cp) and celecoxib (Cel) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22:209-211.
35. Goss GD, Stewart DJ, Hirte H, et al.: Initial results of part 2 of a phase I/II pharmacokinetics (PK), pharmacodynamic (PD) and biological activity study of ZD1839 (Iressa): NCIC CTG IND. 122 Proc Am Soc Clin Oncol 2002, 21:59.
36. Rothenberg ML, Lafleur B, Washington MK, et al.: Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer MCRC treated with gefitinib (ZD 1839) Eastern Cooperative Oncology Group study [abstract]. Proc Am Soc Clin Oncol 2004, 23 3000.
37. Oza AM, Townsley CA, Siu LL, et al.: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003, 22:196.
38. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20:7.
39. Saltz L, Meropol NJ, Loehrer PJ, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
40. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003, 22:252.
41. Lenz HJ, Mayer RJ, Gold PJ, et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract]. Proc Am Soc Clin Oncol 2004, 23:3510.
42. Yang XD, Jia XC, Corvalan JR, et al.: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38:17-23.
43. Meropol NJ, Berlin J, Hecht JR, et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003, 22:256.
44. Philip PA, Geyer SM, Thomas JP, et al.: Tolerability of OSI-774 (Tarceva) in locally advanced or metastatic hepatocellular (HCC) and biliary (BILI) carcinomas: an interim report [abstract]. Proc Am Soc Clin Oncol 2003, 22:364.
45. Philip PA, Mahoney MR, Thomas JP, et al.: Phase II trial of OSI-774 in patients with hepatocellular and biliary cancer [abstract]. Gastro Cancers Symp 2004, 174.
46. Morgan, JA, Bukowski, RM, Xiong, H, et al.: Preliminary report of a phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:197.
47. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
48. Zhang W, Yun J, Press OA, et al.: Association of cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225) [abstract]. Proc Am Soc Clin Oncol 2004, 23:3518.